Dementia - STAT

First Opinion Podcast By Patrick Skerrett

Listen: An Alzheimer’s scholar on the paradox of declining dementia rates

Biotech By Adam Feuerstein

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm’s slow rollout

First Opinion By Daniel R. George and Peter Whitehouse

The brain health paradox: Dementia rates have fallen even as drugs have failed

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Verily’s moment of truth, Aduhelm’s rocky rollout, & the problem with Covid testing

Politics By Rachel Cohrs

Congress demands documents from FDA on controversial approval of Biogen’s Alzheimer’s drug

In the Lab By Megan Molteni

Discovery of rare mutation in a brain protein adds fuel to debate over cause of Alzheimer’s disease

The Readout LOUD By Damian Garde and Meg Tirrell

Listen: The mRNA gold rush, Delta’s alarming rise, & the next treatment for Alzheimer’s

Pharmalot By Ed Silverman

Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug

Health By Andrew Joseph and Rachel Cohrs

Alzheimer’s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm

dementia alzheimer's disease progression

Adam's Take By Adam Feuerstein

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Biotech By Matthew Herper

Here’s why simply approving Aduhelm can’t guarantee a golden age of Alzheimer’s R&D

D.C. Diagnosis By Nicholas Florko

What happened to the FDA’s toughest regulator?

Biotech By Matthew Herper

Biogen mounts defense of its Alzheimer’s drug, saying ‘misinformation’ is fueling controversy

Biotech By Joanne Silberner

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: The FDA’s future, Biden’s tight ship, & the latest Aduhelm twist

Politics By Rachel Cohrs

The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug

Politics By Rachel Cohrs

FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval

Biotech By Jonathan Saltzman — Boston Globe

‘This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug

D.C. Diagnosis By Nicholas Florko

Biden wants a drug pricing plan in 45 days. Who’s going to write it?

Politics By Rachel Cohrs and Ed Silverman

Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug

Politics By Rachel Cohrs

Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

Biotech By Damian Garde, Adam Feuerstein, Matthew Herper and Nicholas Florko

FDA calls for federal investigation into its controversial Alzheimer’s drug approval

Exclusive By Nicholas Florko, Ed Silverman, Rachel Cohrs and Damian Garde

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Most Read

Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures

How Biogen found a believer: At the FDA, a hard-nosed regulator was won over on controversial Alzheimer’s drug

Using human brain tissue in lab dishes, researchers show herpes link to Alzheimer’s

Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug

Role of seizures in Alzheimer’s disease is gaining overdue attention

Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

Will controversy over new Alzheimer’s drug spell the end for the FDA’s faster approval process?

All Coverage

Listen: An Alzheimer’s scholar on the paradox of declining dementia rates

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

Listen: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm’s slow rollout

The brain health paradox: Dementia rates have fallen even as drugs have failed

Listen: Verily’s moment of truth, Aduhelm’s rocky rollout, & the problem with Covid testing

Congress demands documents from FDA on controversial approval of Biogen’s Alzheimer’s drug

Discovery of rare mutation in a brain protein adds fuel to debate over cause of Alzheimer’s disease

Listen: The mRNA gold rush, Delta’s alarming rise, & the next treatment for Alzheimer’s

Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug

Alzheimer’s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Here’s why simply approving Aduhelm can’t guarantee a golden age of Alzheimer’s R&D

What happened to the FDA’s toughest regulator?

Biogen mounts defense of its Alzheimer’s drug, saying ‘misinformation’ is fueling controversy

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Listen: The FDA’s future, Biden’s tight ship, & the latest Aduhelm twist

The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug

FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval

‘This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug

Biden wants a drug pricing plan in 45 days. Who’s going to write it?

Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug

Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

FDA calls for federal investigation into its controversial Alzheimer’s drug approval

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

Listen: Aduhelm’s latest twist, how Covid variants are shaping the summer, & a digital health boom